CDA | Evidence Driven
CDA | Evidence Driven

Stivarga for Unresectable Hepatocellular Carcinoma (HCC) – Details

Details

Files
Generic Name:
Regorafenib
Project Status:
Complete
Therapeutic Area:
Unresectable Hepatocellular Carcinoma (HCC)
Manufacturer:
Bayer Inc.
Brand Name:
Stivarga
Project Line:
Reimbursement Review
Project Number:
PC0119-000
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Strength:
40 mg
Tumour Type:
Gastrointestinal
Indications:
Unresectable Hepatocellular Carcinoma (HCC)
Funding Request:
For treatment of patients with unresectable hepatocellular carcinoma (HCC) who have been previously treated with sorafenib
Sponsor:
Bayer Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Regorafenib (Stivarga) Unresectable Hepatocellular Carcinoma – pERC Final Recommendation Final Recommendation April 18, 2018 View PDF
Regorafenib (Stivarga) Unresectable Hepatocellular Carcinoma – Final Clinical Guidance Report Guidance Reports April 18, 2018 View PDF
Regorafenib (Stivarga) Unresectable Hepatocellular Carcinoma – Final Economic Guidance Report Guidance Reports April 18, 2018 View PDF
Regorafenib (Stivarga) Unresectable Hepatocellular Carcinoma – pERC Initial Recommendation Initial Recommendation March 29, 2018 View PDF
Regorafenib (Stivarga) Unresectable Hepatocellular Carcinoma – PAG Feedback on Initial Recommendation Feedback April 18, 2018 View PDF
Regorafenib (Stivarga) Unresectable Hepatocellular Carcinoma – Manufacturer Feedback on Initial Recommendation Feedback April 18, 2018 View PDF
Regorafenib (Stivarga) Unresectable Hepatocellular Carcinoma – Patient Group Feedback on Initial Recommendation Feedback April 18, 2018 View PDF
Regorafenib (Stivarga) Unresectable Hepatocellular Carcinoma – Clinician Feedback on Initial Recommendation Feedback April 18, 2018 View PDF
Regorafenib (Stivarga) Unresectable Hepatocellular Carcinoma – Patient Group COI Declarations COI Declarations April 18, 2018 View PDF
Regorafenib (Stivarga) Unresectable Hepatocellular Carcinoma – Clinician COI Declarations COI Declarations April 18, 2018 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : May 3, 2018